Issuu on Google+

Agenda Item 11 Enclosure CKWCB/12/86

NHS Calderdale, Kirklees and Wakefield District Cluster Board Report To:

Cluster Board Meeting – 27 March 2012

Title:

Pharmacy Panel Terms of Reference

FOI Exemption Category

Open

Lead Director and contact details:

Sue Cannon, Executive Director of Quality and Governance (Nursing) Tel: 01484 464240 email: sue.cannon@calderdale.nhs.uk

Author Name and contact details:

Vicky Pickles, Head of Corporate Affairs, NHS Calderdale Tel: 01422 281418 email: victoria.pickles@calderdale.nhs.uk

Key Points to Note:

Following clustering, the governance arrangements for Pharmacy Panels have been unclear and therefore as agreed by the Cluster Board at its meeting in October, existing arrangements have remained in place New guidance has been released which requires primary care trusts to formally re-state the delegated arrangements regarding Pharmacy Panels. Alongside this resilience issues at Director and Non Executive level mean that revised terms of reference for the Pharmacy Panel would are required.

Recommendation:

It is recommended that the Board: i.

ii.

Receives the report and approves the proposal for the establishment of a single Pharmacy Panel on behalf of Calderdale, Kirklees and Wakefield District Primary Care Trusts. Approves the terms of reference for the Pharmacy Panel.

Page 1 of 3 21/03/2012


1.

Purpose of Report 1.1. Following clustering, the governance arrangements for Pharmacy Panels have been unclear and therefore as agreed by the Cluster Board at its meeting in October, existing arrangements have remained in place 1.2.

2.

3.

New guidance has been released which requires primary care trusts (PCTs) to formally re-state the delegated arrangements regarding Pharmacy Panels. Alongside this resilience issues at Director and Non Executive level mean that revised terms of reference for the Pharmacy Panel would are required.

Current position 2.1.

Last October, the newly formed Cluster Board agreed new governance arrangements for its sub-committee structure. It was recognised at that time that there were some smaller committees in each of the three primary care trusts where the impact of the changes was less clear. In these instances it was agreed that arrangements would remain unchanged.

2.2.

Each primary care trust has its own Pharmacy Panel in place with different terms of reference, membership and reporting arrangements.

2.3.

Reductions in capacity at a Director level, increased demands on the time of non executive directors and senior staff mean that the Pharmacy Panels need to be brought together to a single process across the Cluster.

2.4.

In addition, new guidance has been released requiring Boards to directly delegate responsibility for the Pharmacy Needs Assessment to an appropriate committee or individual.

Guidance regarding Pharmacy Needs Assessment 3.1.

The White Paper Pharmacy in England: Building on strengths – delivering the future was published by the Department of Health in April 2008. It highlighted the variation in the structure and data requirements of PCT pharmaceutical needs assessments (PNAs) and confirmed that they required further review and strengthening to ensure they are an effective and robust commissioning tool which supports PCT decisions.

3.2.

The Health Act 2009 amended the National Health Service Act 2006 to include provisions for regulations to set out the minimum standards for PNAs. The NHS (Pharmaceutical Services and Local Pharmaceutical Services) (Amendment) Regulations 20102 (the 2010 Regulations) came into force on 24 May 2010 and placed a statutory duty on each PCT to develop and publish their first PNA by 1February 2011 and to publish a revised assessment within three years of its previous one.

3.3.

PCTs are required to keep their PNAs up-to-date and, where they identify changes to the availability of pharmaceutical services, to either revise the assessment and/or issue a supplementary statement.

3.4.

There is a need therefore for a review to be undertaken and a decision made as to whether the PNA is sufficient.

3.5.

The Board should formally delegate the responsibilities relating to revising PNAs and supplementary statements to a committee, subcommittee or officer of the PCT. Page 2 of 3 21/03/2012


3.6.

4.

Given that the Pharmacy Panel is the committee which is most likely to make or have made decisions which would affect the PNA, this is the best committee to consider the revisions.

Terms of reference 4.1. The attached terms of reference set out the proposed new arrangements. This would be that the Cluster Board (on behalf of Calderdale, Kirklees and Wakefield District PCTs) establishes a Pharmacy Panel which will operate on behalf of the three PCTs with these revised terms of reference. 4.2.

It is proposed that there will be one panel with NED, a Cluster Director and a Head of Medicines Management from across the three PCTs. The Panel will have split agenda for the three areas and a clinical pharmacy lead to advise.

4.3.

The lead manager from each area will attend the Panel to present the cases for their area at the appropriate point on the agenda.

4.4.

The approach to the PNA has been considered by the Pharmacy leads and their recommendations incorporated into the TORs

5. Recommendations It is recommended that the Board: iii.

iv.

Receives the report and approves the proposal for the establishment of a single Pharmacy Panel on behalf of Calderdale, Kirklees and Wakefield District Primary Care Trusts. Approves the terms of reference for the Pharmacy Panel.

Page 3 of 3 21/03/2012


/CKWCB-12-86a_Pharmacy_Panel_Te